CN116139078A - 鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用 - Google Patents
鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用 Download PDFInfo
- Publication number
- CN116139078A CN116139078A CN202310192662.2A CN202310192662A CN116139078A CN 116139078 A CN116139078 A CN 116139078A CN 202310192662 A CN202310192662 A CN 202310192662A CN 116139078 A CN116139078 A CN 116139078A
- Authority
- CN
- China
- Prior art keywords
- sphingosine
- bone
- angiogenesis
- promote
- cortical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 title claims abstract description 28
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 title claims abstract description 28
- 230000001054 cortical effect Effects 0.000 title claims abstract description 14
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 230000001737 promoting effect Effects 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 210000000988 bone and bone Anatomy 0.000 title abstract description 30
- 229940079593 drug Drugs 0.000 title description 5
- 230000035515 penetration Effects 0.000 title description 4
- 239000000243 solution Substances 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 13
- 230000007547 defect Effects 0.000 abstract description 13
- 210000002889 endothelial cell Anatomy 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 210000002449 bone cell Anatomy 0.000 abstract description 6
- 230000000149 penetrating effect Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 4
- 230000005012 migration Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 210000003470 mitochondria Anatomy 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 230000019491 signal transduction Effects 0.000 abstract description 2
- 150000003408 sphingolipids Chemical class 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 description 3
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 2
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 2
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940080817 rotenone Drugs 0.000 description 2
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用。鞘氨醇属于鞘脂类，为细胞膜组成成分之一，介导细胞凋亡，血管生成等信号通路。研究结果显示，骨细胞对内皮细胞存活具有重要作用，骨细胞通过对内皮细胞转移线粒体，提高内皮细胞内的鞘氨醇表达水平，促进骨穿皮质血管的生成。体外细胞实验证实补充鞘氨醇可以显著促进血管内皮细胞的增殖，迁移，成管。将鞘氨醇用于治疗骨折或骨缺损，可以促进骨穿皮质血管生成，促进骨折和骨缺损愈合。
Description
技术领域
本发明涉及骨缺损愈合技术领域，尤其涉及鞘氨醇溶液在制备促进骨穿皮质血管生成的药物中的应用。
背景技术
骨缺损常见于肿瘤切除、先天性畸形、骨折、关节置换翻修等情况，直接影响病人的肢体活动，甚至对生活质量和生命安全造成影响。临床中治疗骨缺损常采用自体骨移植，异体骨移植和植入金属修复材料。但自体骨移植可能会造成供体部位疾病的发生，包括运动受限、感知障碍和疼痛等问题；异体骨则可能导致排异和不愈合；植入金属修复材料则存在高弹性模量、高摩擦因数、细胞毒性和潜在的过敏风险等问题。因此诱导患者骨缺损自发修复具有重要意义。
骨穿皮质血管广泛分布于皮质骨，承载了骨内外主要的血流运输，细胞转移等功能。骨折后，骨穿皮质血管的丰富程度直接影响骨缺损的愈合速度。缺乏血管的区域，愈合速度较慢，甚至导致骨不愈合。因此，骨穿皮质血管的对骨缺损的愈合发挥重要作用。然而目前尚无聚焦于促进骨穿皮质血管生成，从而促进骨缺损愈合的药物。
发明内容
本发明的目的是针对现有技术中的不足，提供鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用。
为实现上述目的，本发明采取的技术方案是：
提供鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用。
进一步地，所述鞘氨醇溶液的浓度为12.5～50nmol/L。
进一步地，所述鞘氨醇溶液的溶剂为生理盐水。
进一步地，所述药物的剂型为口服剂和注射剂。
本发明采用以上技术方案，与现有技术相比，具有如下技术效果：
鞘氨醇属于鞘脂类，为细胞膜组成成分之一，介导细胞凋亡，血管生成等信号通路。研究结果显示，骨细胞对内皮细胞存活具有重要作用，骨细胞通过对内皮细胞转移线粒体，提高内皮细胞内的鞘氨醇表达水平，促进骨穿皮质血管的生成。体外细胞实验证实补充鞘氨醇可以显著促进血管内皮细胞的增殖，迁移，成管。将鞘氨醇用于骨折活骨缺损处，可以促进骨穿皮质血管生成，促进骨折和骨缺损愈合。
附图说明
图1为本发明实施例1中细胞的ROS水平的测定结果图；
图2为本发明实施例1中CCK8实验的结果图；
图3为本发明实施例1中成管实验的结果图；
图4为本发明实施例1中划痕实验的结果图。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明，但不作为本发明的限定。需要说明的是，在不冲突的情况下，本发明中的实施例及实施例中的特征可以相互组合。
实施例1
将鞘氨醇溶于生理盐水分别配制浓度为12.5nmol/L、25nmol/L、50nmol/L的鞘氨醇溶液，采用高糖DMEM培养基，细胞实验使用bEnd.3细胞系，分为5组，分别为正常细胞组，2μM抗霉素A/鱼藤酮损伤组，以及2μM抗霉素A/鱼藤酮损伤并额外接受12.5nmol/L、25nmol/L、50nmol/L的鞘氨醇溶液干预组。
1)采用流式细胞术测定不同组内的细胞的ROS水平，结果如图1所示，可发现鞘氨醇干预后，损伤细胞ROS水平下降。
2)CCK8实验结果如图2所示，可见鞘氨醇干预后，损伤细胞增殖速度恢复。
3)成管实验结果如图3所示，可见鞘氨醇干预后，损伤细胞的成管能力恢复。
4)划痕实验结果如图4所示，可见鞘氨醇干预后，损伤细胞的迁移能力恢复。
研究结果显示，骨细胞对内皮细胞存活具有重要作用，骨细胞通过对内皮细胞转移线粒体，提高内皮细胞内的鞘氨醇表达水平，促进骨穿皮质血管的生成。体外细胞实验证实补充鞘氨醇可以显著促进血管内皮细胞的增殖，迁移，成管。将鞘氨醇用于骨折活骨缺损处，可以促进骨穿皮质血管生成，促进骨折和骨缺损愈合。
上所述仅为本发明较佳的实施例，并非因此限制本发明的实施方式及保护范围，对于本领域技术人员而言，应当能够意识到凡运用本发明说明书内容及图示所作出的等同替换和显而易见的变化所得到的方案，均应当包含在本发明的保护范围内。
Claims (4)
1.鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述鞘氨醇溶液的浓度为12.5～50nmol/L。
3.根据权利要求1所述的应用，其特征在于，所述鞘氨醇溶液的溶剂为生理盐水。
4.根据权利要求1所述的应用，其特征在于，所述药物的剂型为注射剂和口服剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310192662.2A CN116139078A (zh) | 2023-03-02 | 2023-03-02 | 鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310192662.2A CN116139078A (zh) | 2023-03-02 | 2023-03-02 | 鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116139078A true CN116139078A (zh) | 2023-05-23 |
Family
ID=86354332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310192662.2A Withdrawn CN116139078A (zh) | 2023-03-02 | 2023-03-02 | 鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116139078A (zh) |
-
2023
- 2023-03-02 CN CN202310192662.2A patent/CN116139078A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chan et al. | The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury | |
| Cai et al. | Anti-inflammatory and prochondrogenic in situ-formed injectable hydrogel crosslinked by strontium-doped bioglass for cartilage regeneration | |
| Ahmed et al. | Advances in medical and surgical engineering | |
| Quan et al. | Application of biomaterials in treating early osteonecrosis of the femoral head: Research progress and future perspectives | |
| Ehmke et al. | Treatment of osteonecrosis in systemic lupus erythematosus: a review | |
| JP2022058550A (ja) | 関節痛を緩和する方法 | |
| Lee et al. | Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. | |
| US20220233585A1 (en) | Mononuclear-rich, platelet-rich plasma compositions and methods of use thereof | |
| CN116139078A (zh) | 鞘氨醇溶液在制备促进骨穿皮质血管生成药物中的应用 | |
| US9393269B2 (en) | Rapid infusion of autologous bone marrow derived stem cells | |
| CN102441023A (zh) | 一种治疗骨科疾病的注射用组合物 | |
| Basnaev et al. | Platelet-rich plasma administering in osteoarthrosis treatment | |
| CN101549177B (zh) | 一种用于脊柱内固定术螺钉的药物涂层及制备和应用 | |
| Gupta | Commentary: cell-free stem cell-derived extract formulation for treatment of knee osteoarthritis | |
| Yang et al. | PRP therapies (tendons, joints, spine) | |
| Zhu et al. | Bioengineering strategies targeting angiogenesis: Innovative solutions for osteonecrosis of the femoral head | |
| Businco et al. | New technologies for the prevention and treatment of empty nose syndrome: minimally invasive and regenerative surgery with PRL | |
| RU2546295C1 (ru) | Способ лечения коксартроза четвертой степени | |
| Upadhyay et al. | EFFICACY OF AUTOLOGOUS PLATELET-RICH PLASMA INJECTION IN KNEE OSTEOARTHRITIS | |
| RU2803958C1 (ru) | Аспирационно-компрессионный способ лечения локтевого бурсита | |
| von Rickenbach et al. | Orthobiologics | |
| Al-Edanni | Chronic Tennis Elbow Treated by Platelet-Rich Plasma Versus Steroid Injections: A Comparative Study | |
| Pimenta et al. | Shoulder Injections: Options, Ultrasound Assistance, Evidences | |
| ES2605813B1 (es) | Uso de osteostatina en la preparación de un medicamento para el tratamiento de artrosis | |
| Moshref et al. | Intra-articular injection of autologous fat graft for the treatment of knee osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230523 |
|
| WW01 | Invention patent application withdrawn after publication |